9 results on '"Shan-Rong Shi"'
Search Results
2. Standardization of Immunohistochemistry Based on Antigen Retrieval Technique for Routine Formalin-fixed Tissue Sections
- Author
-
Benjaporn Chaiwun, Taiying Chen, Yan Shi, Shan Rong Shi, Clive R. Taylor, Richard J. Cote, Debra Hawes, and Lillian L. Young
- Subjects
Medical Laboratory Technology ,chemistry.chemical_compound ,Pathology ,medicine.medical_specialty ,Tissue sections ,Antigen retrieval ,chemistry ,medicine ,Immunohistochemistry ,Formalin fixed ,Anatomy - Published
- 1998
3. Detection of Occult Bone Marrow Micrometastases in Patients with Operable Lung Carcinoma
- Author
-
Shan Rong Shi, Clive R. Taylor, Richard J. Cote, Benjaporn Chaiwun, James Harvey, Andy Sherrod, Su Chiu Chen, Edward J. Beattie, and Susan Groshen
- Subjects
medicine.medical_specialty ,Systemic disease ,Pathology ,Lung Neoplasms ,Gastroenterology ,Epithelium ,Metastasis ,Antigens, Neoplasm ,Risk Factors ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,medicine ,Adjuvant therapy ,Carcinoma ,Humans ,Stage (cooking) ,Lung cancer ,business.industry ,Respiratory disease ,Antibodies, Monoclonal ,medicine.disease ,Immunohistochemistry ,Survival Rate ,medicine.anatomical_structure ,Keratins ,Surgery ,Bone marrow ,Neoplasm Recurrence, Local ,Bone Marrow Neoplasms ,business ,Research Article - Abstract
OBJECTIVES: A large proportion of patients with operable lung carcinoma (no evidence of systemic spread of tumor) develop metastatic disease after primary therapy. More sensitive and specific methods are needed to identify patients at highest risk for recurrence who may benefit most from adjuvant therapy, while sparing those patients who do not require such treatment. SUMMARY BACKGROUND DATA: Using epithelial-specific monoclonal antibodies, the authors have developed an immunocytochemical assay capable of detecting as few as 2 lung cancer cells in 1 million bone marrow cells. METHODS: The assay was used to test the bone marrow (from resected ribs) of 43 patients with primary non-small cell lung carcinoma who showed no clinical or pathologic evidence of systemic disease. RESULTS: Occult bone marrow micrometastases (BMMs) were detected in 40% of patients (17/43) with non-small cell lung cancer, including 29% (5/17) of patients with stage I or II disease and 46% of whom (12/26) had stage III disease. The median follow-up was 13.6 months. Patients with occult BMMs had significantly shorter times to disease recurrence compared with patients without BMMs (7.3 vs. > 35.1 months, p = 0.0009). Furthermore, for patients with stage I or II disease, the presence of occult BMMs was significantly associated with a higher rate of recurrence (p = 0.0004). CONCLUSIONS: The detection of occult BMMs identifies patients with operable non-small cell lung carcinoma who are at significantly increased risk for recurrence, independent of tumor stage, and may be useful in evaluating patients for adjuvant treatment protocols.
- Published
- 1995
4. Re: Combination of Molecular Alterations and Smoking Intensity Predicts Bladder Cancer Outcome: A Report from the Los Angeles Cancer Surveillance Program
- Author
-
Denice D. Tsao-Wei, Susan Groshen, Victoria K. Cortessis, Xuejuan Jiang, Anirban P. Mitra, Jose E. Castelao, Donald G. Skinner, Debra Hawes, Mimi C. Yu, Ram H. Datar, Richard J. Cote, Ronald K. Ross, Eila C. Skinner, John P. Stein, and Shan Rong Shi
- Subjects
Oncology ,Cancer Research ,Pathology ,medicine.medical_specialty ,Urology ,Population ,Outcome (game theory) ,Article ,Cohort Studies ,Predictive Value of Tests ,Internal medicine ,Adjuvant therapy ,Biomarkers, Tumor ,medicine ,Humans ,Registries ,education ,Aged ,Gynecology ,education.field_of_study ,Bladder cancer ,business.industry ,Smoking ,Cancer ,Middle Aged ,Cadherins ,Prognosis ,medicine.disease ,Los Angeles ,Cancer registry ,Intensity (physics) ,Apoptotic Protease-Activating Factor 1 ,Treatment Outcome ,Urinary Bladder Neoplasms ,Predictive value of tests ,Multivariate Analysis ,Cohort ,Biomarker (medicine) ,Tumor Suppressor Protein p53 ,business ,Follow-Up Studies ,Cohort study - Abstract
BACKGROUND: Traditional single-marker and multimarker molecular profiling approaches in bladder cancer do not account for major risk factors and their influence on clinical outcome. This study examined the prognostic value of molecular alterations across all disease stages after accounting for clinicopathological factors and smoking, the most common risk factor for bladder cancer in the developed world, in a population-based cohort. METHODS: Primary bladder tumors from 212 cancer registry patients (median follow-up, 13.2 years) were immunohistochemically profiled for Bax, caspase-3, apoptotic protease-activating factor 1 (Apaf-1), Bcl-2, p53, p21, cyclooxygenase-2, vascular endothelial growth factor, and E-cadherin alterations. “Smoking intensity” quantified the impact of duration and daily frequency of smoking. RESULTS: Age, pathological stage, surgical modality, and adjuvant therapy administration were significantly associated with survival. Increasing smoking intensity was independently associated with worse outcome (P < .001). Apaf-1, E-cadherin, and p53 were prognostic for outcome (P = .005, .014, and .032, respectively); E-cadherin remained prognostic following multivariable analysis (P = .040). Combined alterations in all 9 biomarkers were prognostic by univariable (P < .001) and multivariable (P = .006) analysis. A multivariable model that included all 9 biomarkers and smoking intensity had greater accuracy in predicting prognosis than models composed of standard clinicopathological covariates without or with smoking intensity (P < .001 and P = .018, respectively). CONCLUSIONS: Apaf-1, E-cadherin, and p53 alterations individually predicted survival in bladder cancer patients. Increasing number of biomarker alterations was significantly associated with worsening survival, although markers comprising the panel were not necessarily prognostic individually. Predictive value of the 9-biomarker panel with smoking intensity was significantly higher than that of routine clinicopathological parameters alone. Cancer 2013. © 2013 American Cancer Society.
- Published
- 2013
5. Re: Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status
- Author
-
David Esrig, Derek Raghavan, Gary D. Steinberg, Seth P. Lerner, Richard J. Cote, Donald G. Skinner, Walter M. Stadler, Shan Rong Shi, Darien Wood, Laurence Klotz, Susan Groshen, Craig Hall, and John P. Stein
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Urology ,Locally advanced ,Vinblastine ,Article ,Immunoenzyme Techniques ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Original Reports ,P53 status ,Carcinoma ,Adjuvant therapy ,Humans ,Medicine ,Urothelial cancer ,Molecular Targeted Therapy ,Prospective Studies ,Prospective cohort study ,Survival rate ,Aged ,Carcinoma, Transitional Cell ,Bladder cancer ,business.industry ,Carcinoma in situ ,Retrospective cohort study ,medicine.disease ,Survival Rate ,Methotrexate ,Treatment Outcome ,Urinary Bladder Neoplasms ,Doxorubicin ,Female ,Cisplatin ,Tumor Suppressor Protein p53 ,business ,Carcinoma in Situ ,Follow-Up Studies ,medicine.drug - Abstract
Introduction Retrospective studies suggest that p53 alteration is prognostic for recurrence in patients with urothelial bladder cancer and predictive for benefit from combination methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) adjuvant chemotherapy. Patients and Methods Patients with pT1/T2N0M0 disease whose tumors demonstrated ≥ 10% nuclear reactivity on centrally performed immunohistochemistry for p53 were offered random assignment to three cycles of adjuvant MVAC versus observation; p53-negative patients were observed. By using a log-rank test with one-sided α = .05 and β = .10, 190 p53-positive patients were planned to be randomly assigned to detect an absolute improvement in probability of recurring by 3 years from 0.50 to 0.30. Results A total of 521 patients were registered, 499 underwent p53 assessment, 272 (55%) were positive, and 114 (42%) were randomly assigned. Accrual was halted on the basis of the data and safety monitoring board review of a futility analysis. Overall 5-year probability of recurring was 0.20 (95% CI, 0.16 to 0.24) with no difference on the basis of p53 status. Only 67% of patients randomly assigned to MVAC received all three cycles with 12 patients receiving no treatment. There was no difference in recurrence in the randomly assigned patients (hazard ratio, 0.78; 95% CI, 0.29 to 2.08; P = .62). Conclusion Neither the prognostic value of p53 nor the benefit of MVAC chemotherapy in patients with p53-positive tumors was confirmed, but the high patient refusal rate, lower than expected event rate, and failures to receive assigned therapy severely compromised study power.
- Published
- 2012
6. Elevated and Absent pRb Expression is Associated With Bladder Cancer Progression and has Cooperative Effects With p53
- Author
-
William F. Benedict, John P. Stein, Matthew D. Dunn, Clive R. Taylor, Donald G. Skinner, Susan Groshen, Shan Rong Shi, S.X. Hu, Sunanda J. Chatterjee, R.J. Corte, H.J. Xu, and Q.-C. Tran
- Subjects
Oncology ,medicine.medical_specialty ,Bladder cancer ,business.industry ,Urology ,medicine.medical_treatment ,Tumor cells ,medicine.disease ,law.invention ,Cystectomy ,Transitional cell carcinoma ,law ,Tumor progression ,Internal medicine ,medicine ,Cancer research ,Suppressor ,biological phenomena, cell phenomena, and immunity ,Rb Protein ,business ,neoplasms ,P53 expression - Abstract
Rb protein (pRb) expression was evaluated in 185 cases of transitional cell carcinoma of the bladder from patients that underwent radical cystectomy. Tumors were stratified into three categories based on the percentage of nuclei expressing pRb: (a) 0, 0% of tumor cells showing nuclear reactivity; (In \+, 1-50% of tumor cells showing nuclear reactivity; and (c)2+, >50% of tumor cells showing nuclear reactivity. Cases with undetectable (pRb 0) and high (pRb 2+) pRb reactivity had identical rates of recurrence. These cases had significantly higher recurrence (P = 0.0001) and lower survival rates i/' = 0.0002) compared to cases with moderate (pRb 1+ ) pRb reactivity, indicating that high levels of pRb expression may reflect a dysfunctional (altered) Rb pathway. The tumors were also examined for alterations in p53 expression; patients with tumors altered in both p53 and pRb had signifi cantly increased rates of recurrence (P < 0.0001) and survival (P < 0.0001) compared to patients with no alterations in either p53 or pRb; patients with alterations in only one of these proteins had intermediate rates of recurrence and survival. These results suggest that: (a) bladder cancers with high pRb expression do not show the tumor suppressor effects of the protein; and (In alteration in both p53 and pRb may act in cooperative or synergistic ways to promote tumor progression.
- Published
- 1998
7. Sensitivity and Detection Efficiency of a Novel Two-Step Detection System (PowerVision) for Immunohistochemistry
- Author
-
Shan-Rong Shi, James Guo, Richard J. Cote, Lillian L. Young, Debra Hawes, Yan Shi, Sandra Thu, and Clive R. Taylor
- Subjects
Medical Laboratory Technology ,Histology ,Pathology and Forensic Medicine - Published
- 1999
8. [Untitled]
- Author
-
Clive R. Taylor, James Guo, Shan Rong Shi, Lillian L. Young, Yan Shi, Debra Hawes, Sandra Thu, and Richard J. Cote
- Subjects
Medical Laboratory Technology ,chemistry.chemical_compound ,Antigen retrieval ,chemistry ,Two step ,Immunohistochemistry ,Sensitivity (control systems) ,Anatomy ,Molecular biology - Published
- 1999
9. THE COMBINED EFFECTS OF p53, p21, and Rb EXPRESSION IN BLADDER CANCER PROGRESSION
- Author
-
David Youssefzadeh, Shan-Rong Shi, Sunanda J. Chatterjee, John P. Stein, Susan Groshen, Donald G. Skinner, and Richard J. Cote
- Subjects
Oncology ,medicine.medical_specialty ,Bladder cancer ,Expression (architecture) ,business.industry ,Urology ,Internal medicine ,medicine ,medicine.disease ,business - Published
- 1999
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.